Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients

被引:25
|
作者
Karabon, L. [1 ,2 ]
Partyka, A. [1 ]
Ciszak, L. [1 ]
Pawlak-Adamska, E. [1 ]
Tomkiewicz, A. [1 ]
Bojarska-Junak, A. [3 ]
Rolinski, J. [3 ]
Wolowiec, D. [4 ]
Wrobel, T. [4 ]
Frydecka, I. [1 ]
Kosmaczewska, A. [1 ]
机构
[1] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Therapy, Wroclaw, Poland
[2] Wroclaw Med Univ, Dept & Clin Urol & Oncol Urol, Wroclaw, Poland
[3] Med Univ Lublin, Dept Clin Immunol & Immunotherapy, Lublin, Poland
[4] Wroclaw Med Univ, Dept & Clin Haematol Blood Neoplasms & Bone Marro, Wroclaw, Poland
关键词
CD8(+) T-CELLS; B-LYMPHOCYTE; INFECTIOUS COMPLICATIONS; MEDIATES INHIBITION; CYCLE REGULATORS; CD152; CTLA-4; ATTENUATOR; RECEPTOR; CANCER; PROLIFERATION;
D O I
10.1155/2020/6545921
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic lymphocytic leukemia (CLL) is characterized by the peripheral accumulation of neoplastic B cells and is frequently complicated by the systemic immunosuppression associated with an impairment in B and T lymphocyte activation. We hypothesized that the expression of immune checkpoint suppressors B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte antigen (CTLA-4) is disturbed in both lymphocyte subpopulations in CLL. The expression of CTLA-4 and BTLA mRNA was determined by real-time PCR, while CTLA-4 protein expression (surface or intracellular) was estimated in BTLA+ lymphocytes by flow cytometry. In CLL patients, we observed a higher gene transcript level of BTLA and CTLA-4 than in healthy individuals in both freshly isolated and PMA stimulated B and T cells. Remarkably, lower amounts of both inhibitory proteins were found in peripheral blood (PB) CLL B cells, whereas normal BTLA and elevated CTLA-4 were found in T cells. Consistently, there was a prevalence of CTLA-4+ cells within circulating BTLA+ T cells cells of patients confronting PB healthy cells. After in vitro stimulation, the only change found in CLL patients was a decrease in BTLA expression in B and T lymphocytes. In contrast, healthy lymphocytes responded more vigorously as regards the BTLA and CTLA expression with substantially higher frequency of CD69+ cells under the stimulating condition compared to corresponding cells from the CLL group. Our results indicate that CLL development is associated with the affected expression of BTLA and CTLA-4 checkpoint receptors in PB and its impaired expression might be associated with lowering of the threshold for B cell activation and proliferation, while upregulated CTLA-4 expression in CLL peripheral BTLA+ T cells may contribute to suppressed T cell effector functions. This hypothesis needs to be validated in future studies, which would allow us to explain how the increased or decreased expression of these molecules affects the cell function.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia
    Taghiloo, Saeid
    Asgarian-Omran, Hossein
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (10) : 1408 - 1438
  • [22] Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia
    Saeid Taghiloo
    Hossein Asgarian-Omran
    Current Treatment Options in Oncology, 2023, 24 : 1408 - 1438
  • [23] Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models.
    Selby, Mark
    Engelhardt, John
    Lu, Li-Sheng
    Quigley, Michael
    Wang, Changyu
    Chen, Bingliang
    Korman, Alan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Expression of TIGIT, BTLA, LAG3, FCRL3 and CTLA-4 in Sezary Syndrome
    Anzengruber, Florian
    Ignatova, Desislava
    Eberle-Schlapfer, Tanja
    Chang, Yun-Tsan
    French, Lars
    Guenova, Emmanuella
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : S5 - S5
  • [25] Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    Qin, Shuang
    Xu, Linping
    Yi, Ming
    Yu, Shengnan
    Wu, Kongming
    Luo, Suxia
    MOLECULAR CANCER, 2019, 18 (01)
  • [26] Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4), and CD137 in cervical carcinoma
    Kassardjian, Ari
    Moatamed, Neda A.
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2021, 14 (10): : 1038 - +
  • [27] The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
    Hahn, Andrew W.
    Gill, David M.
    Pal, Sumanta K.
    Agarwal, Neeraj
    IMMUNOTHERAPY, 2017, 9 (08) : 681 - 692
  • [28] Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    Shuang Qin
    Linping Xu
    Ming Yi
    Shengnan Yu
    Kongming Wu
    Suxia Luo
    Molecular Cancer, 18
  • [29] Gene polymorphisms of costimulatory molecules: CTLA-4/CD28/ICOS are associated with B-Cell chronic lymphocytic leukemia (B-CLL)
    Frydecka, Irena
    Suwalska, Katarzyna
    Pawlak, Edyta
    Karabon, Lidia
    Tomkiewicz, Anna
    Dobosz, Tadeusz
    Urbaniak-Kujda, Donata
    Kuliczkowski, Kazimierz
    Wolowiec, Dariusz
    BLOOD, 2007, 110 (11) : 618A - 618A
  • [30] TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia
    Seiffert, Martina
    HAEMATOLOGICA, 2023, 108 (08) : 1979 - 1981